Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four cases

Br J Haematol. 1998 Jul;102(2):532-4. doi: 10.1046/j.1365-2141.1998.00792.x.

Abstract

We report four patients with relapsed or refractory follicular (three) and lymphoplasmacytic (one) lymphoma who achieved complete remission (CR) with fludarabine (FDR) lasting from 3.2 to 6 years. One had stage III and three stage IV and were resistant to chlorambucil and/or anthracycline. FDR was well tolerated, the only complication being herpes zoster infection in three patients, which was controlled with aciclovir. One patient developed a gastric MALT lymphoma from a different clone than the follicular lymphoma. In conclusion, some patients with refractory low-grade lymphoma achieve long-term CR with FDR: therefore this agent may be considered as alternative to stem-cell transplantation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anthracyclines / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chlorambucil / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Lymphoma, Follicular / drug therapy*
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Male
  • Middle Aged
  • Prednisone / therapeutic use
  • Vidarabine / analogs & derivatives*
  • Vidarabine / therapeutic use
  • Vincristine / therapeutic use

Substances

  • Anthracyclines
  • Antineoplastic Agents
  • Antineoplastic Agents, Alkylating
  • Chlorambucil
  • Vincristine
  • Cyclophosphamide
  • Vidarabine
  • fludarabine
  • Prednisone

Supplementary concepts

  • COP protocol 2